Qwo
Qwo Uses, Dosage, Side Effects, Food Interaction and all others data.
Qwo is an enzyme produced by the bacterium Clostridium histolyticum. It is beneficial in the breakdown of collagen plaques for the treatment of Dupuytren's contracture and Peyronie's disease. The topical formulation is used for the debridement of necrotic tissue due to burns or chronic ulcers.
On July 6, 2020 a combination of injectable bacterial collagenases was approved by the FDA for the treatment of cellulite in adult women. Also known as Qwo, this injection is the first approved injectable treatment for cellulite and was developed by Endo International.
Collagenase digests collagen, treating conditions such as Peyronie's disease, cellulite, chronic ulcers, burns, and contractures.
| Trade Name | Qwo |
| Generic | Collagenase clostridium histolyticum |
| Collagenase clostridium histolyticum Other Names | Clostridiopeptidase A, Clostridium histolyticum enzymes, Collagenase, Collagenase clostridium histolyticum, collagenase clostridium histolyticum-aaes |
| Type | Injection, powder, lyophilized, for solution |
| Formula | C5028H7666N1300O1564S21 |
| Weight | 112023.2 Da |
| Protein binding | There is no readily available information regarding the protein binding of collagenase. |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States, |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Qwo is a collagenase enzyme used to promote debridement of necrotic tissue in burns and skin ulcers as well as to treat Dupuytren's contracture and Peyronie's disease.
Qwo is indicated for the treatment of adults with Dupuytren's contracture with a palpable cord. Additionally, it is used to treat men with Peyronie's disease diagnosed with a penile curvature deformity of at least a 30-degree angle at the beginning of therapy in addition to palpable plaques. Collagenase ointment is used for the tissue debridement of chronic dermal ulcers and severely burned tissues. The combination collagenase product, also known as Qwo, is used for the treatment of moderate to severe cellulite in the buttocks of adult women.
Qwo is also used to associated treatment for these conditions: Dupuytren's Contracture of the Hand (Viking's Disease), Peyronie's Disease, Necrotic tissue
How Qwo works
Peyronie's disease is a fibrous lesion of the tunica albuginea in the penile tissues. Cellulite is a multifactorial condition resulting in the accumulation of fibrotic dermal septae and the expansion of subcutaneous fat. Dupuytren's contracture is a fibroproliferative disease that results in the fibrous deposition of collagen in the hands, limiting mobility and functionality of the hands. The collagen deposition in the abovementioned conditions is the target of collagenase enzyme therapy.
These enzymes are proteinases acting to hydrolyze collagen's triple-helical conformation, resulting in the lysis of collagen deposits and relief from the necrotic tissue and plaques associated with several conditions. On a molecular level, collagenases cleave polypeptide chains that make up the collagen triple helix structure at various loci, leading to solubilization from the collagen fibril.
Toxicity
No clinical reaction has been attributed to an overdose of collagenase in clinical trials. If required, the collagenase enzymes can be inactivated with a povidone-iodine wash.
Food Interaction
No interactions found.Volume of Distribution
There is no currently available information regarding the presence of collagenase in body fluids or uptake by particular organs and passage through the blood-brain barrier. Systemic pharmacokinetic studies evaluation volume of distribution have not been performed, however, collagenase histolyticum is likely to have local degradative effects in the region of the application without effects on the vasculature and elastic tissue.
Elimination Route
There is currently limited readily available regarding the absorption of collagenase through the skin. In a pharmacokinetic study, the serum concentrations of clostridium type I collagenase (AUX-I) and clostridium type II collagenase (AUX-II) were measured. Both were detected under the lower limit of quantitation of 5 ng/mL and 25 ng/mL, respectively, in volunteers administered one dose of the collagenase histolyticum combination product, Qwo, at a dose of up to 3.36 mg in a maximum of 4 body areas.
Clearance
Clearance information for collagenase is not readily available.
Innovators Monograph
You find simplified version here Qwo
